Randall MD - Longboard Pharmaceuticals Executive Officer
| LBPHDelisted Stock | USD 59.98 0.00 0.00% |
Executive
Randall MD is Executive Officer of Longboard Pharmaceuticals
| Age | 62 |
| Phone | 858 789 9283 |
| Web | https://www.longboardpharma.com |
Longboard Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3072) % which means that it has lost $0.3072 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4666) %, meaning that it created substantial loss on money invested by shareholders. Longboard Pharmaceuticals' management efficiency ratios could be used to measure how well Longboard Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Longboard Pharmaceuticals currently holds 475 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Longboard Pharmaceuticals has a current ratio of 11.71, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Longboard Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Steven CPA | NextCure | 61 | |
| Pamela Trail | Molecular Partners AG | 68 | |
| William Winston | Werewolf Therapeutics | N/A | |
| Stacy Rollinger | NextCure | N/A | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| Kendra Adams | C4 Therapeutics | N/A | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Moses Makunje | Nuvation Bio | 45 | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Mr MBA | C4 Therapeutics | 46 | |
| Thomas Rollins | Assembly Biosciences | 68 | |
| Jason Hoitt | Stoke Therapeutics | 46 | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| Brent Eilefson | Celcuity LLC | N/A | |
| Mark Mossler | C4 Therapeutics | 51 | |
| Richard Colonno | Assembly Biosciences | 74 | |
| Karin Heidemann | Champions Oncology | N/A | |
| Isabel Chiu | C4 Therapeutics | N/A | |
| MS MBA | Sensei Biotherapeutics | 46 | |
| Courtney Solberg | C4 Therapeutics | N/A | |
| Huw Nash | Stoke Therapeutics | 57 | |
Management Performance
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.31 |
Longboard Pharmaceuticals Leadership Team
Elected by the shareholders, the Longboard Pharmaceuticals' board of directors comprises two types of representatives: Longboard Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Longboard. The board's role is to monitor Longboard Pharmaceuticals' management team and ensure that shareholders' interests are well served. Longboard Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Longboard Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dewey McLin, VP Affairs | ||
| Jodi Parsons, VP Affairs | ||
| Chadwick MPH, Executive Operations | ||
| Steven JD, Head Counsel | ||
| Randall MD, Executive Officer | ||
| Nuggehally Srinivas, VP Pharmacometrics | ||
| Megan Knight, Head Relations | ||
| Anne Danks, VP Development | ||
| Marco Peters, VP Science | ||
| Kevin Lind, CEO and President | ||
| Gus Cardenas, VP Assurance |
Longboard Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Longboard Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 2.06 B | ||||
| Shares Outstanding | 34.44 M | ||||
| Shares Owned By Insiders | 1.19 % | ||||
| Shares Owned By Institutions | 98.81 % | ||||
| Number Of Shares Shorted | 1.93 M | ||||
| Price To Book | 8.51 X | ||||
| EBITDA | (56.75 M) | ||||
| Net Income | (54.42 M) |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Longboard Stock
If you are still planning to invest in Longboard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Longboard Pharmaceuticals' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |